Compare Novartis AG (NVS) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.47 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is the larger of the two by market cap, and Novartis AG pays a 3.31% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| NVS | VEA | |
|---|---|---|
Market Cap | $274.00B | $323.80B |
Volume | 1,852,137 | 9,762,021 |
Sector | Health | — |
52-Week High | $168.62 | $73.79 |
52-Week Low | $121.80 | $58.90 |
Typical Hold Time | 82 Days | 131 Days |
Enterprise Value | $315.32B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
VEA, the Vanguard FTSE Developed Markets ETF, trades at $70.26, down 1.2% on the day amid a bearish technical signal. The ETF provides cost-efficient exposure to developed markets outside the U.S., with a 0.03% expense ratio and competitive dividend yield. Recent news highlights institutional activity, with firms like Allianz Asset Management increasing stakes while others trimmed positions.
The outlook remains mixed, with technical indicators signaling caution but fundamental strengths in low costs and diversification. Key risks include global market volatility and currency fluctuations. Investors should weigh the ETF's stable, income-oriented profile against near-term bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
